RVMDWStockRevolution Medicines, Inc.
Verdicts genuinely change. Free email alert the moment RVMDW's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Methodology breakdown business activity not assessed▾
AAOIFI ● REVIEW ▾
Usmani ● REVIEW ▾
Dow Jones ● REVIEW ▾
S&P Shariah ● REVIEW ▾
MSCI ● REVIEW ▾
MSCI M ● REVIEW ▾
FTSE ● REVIEW ▾
Business activity could not be assessed — classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later
ℹ️ Ratios above can still show Pass — business-activity screening itself couldn't run, and it's a hard gate a ratio pass can't substitute for.
🔎 Data provenance — sourcing & safeguards behind these numbers
Source: stored filing inputs · Balance sheet as of 2026-06-30 · Income statement as of 2025-12-31
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
🕌 In-house Compliance Research
Research only, not the primary verdict above — computed from SEC EDGAR filings and business-activity classification.
Business activity: could not be assessed
classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later
AAOIFI Standard 21 (% of market cap) — Unverified ⚠️ implied interest rate too low — debt may be double-counted 1 of 3 ratios pass
Usmani (% of total assets) — Unverified ⚠️ implied interest rate too low — debt may be double-counted 1 of 5 ratios pass
Dow Jones Islamic Market (% of 24-mo avg market cap) — Unverified ⚠️ the figures this standard needs were not all available, so it could not be scored — the rows below show which ones are missing 0 of 0 ratios pass
S&P Shariah Indices (% of 36-mo avg market cap) — Unverified ⚠️ the figures this standard needs were not all available, so it could not be scored — the rows below show which ones are missing 0 of 0 ratios pass
MSCI Islamic Index (% of total assets) — Unverified ⚠️ implied interest rate too low — debt may be double-counted 1 of 4 ratios pass
MSCI Islamic M-Series (% of 36-mo avg market cap) — Unverified ⚠️ the figures this standard needs were not all available, so it could not be scored — the rows below show which ones are missing 0 of 0 ratios pass
FTSE Shariah Global Equity Index Series (% of total assets) — Unverified ⚠️ implied interest rate too low — debt may be double-counted 1 of 4 ratios pass
AAOIFI divides by the market cap stored with these figures ($2.3B); this record does not say which day it was fetched, so no estimate for today is made from it.
🔎 Data provenance — sourcing & safeguards behind these numbers
Source: stored filing inputs · Balance sheet as of 2026-06-30 · Income statement as of 2025-12-31
The live recompute of the financial screen did not complete for this symbol, so no combined verdict is shown here. That is a statement about our fetch, not about the company — the stored result above stands.
ℹ️ Every methodology's ratios above may show Pass, but the combined verdict still reads Needs Review because business-activity screening itself couldn't run (classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later) — it's a hard gate, so a real ratio pass can't substitute for it. Re-check this page later once that's resolved.
The three ratios
Computed from the company's own filing, measured against market cap — the AAOIFI basis. Other standards move both the line and the denominator, which is what the breakdown above shows.
The numbers the ratios are built from
Read from RVMDW's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $0 | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $487.4M | 2026-06-30 | ConvertibleLongTermNotesPayable |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $3.9B | 2026-06-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent |
| Total assetsBalance sheet total | $4.3B | 2026-06-30 | Assets |
| Market capDenominator for AAOIFI | $2.3B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | not measured | — | — |
| 24-month average market capDenominator for Dow Jones Islamic Market | not measured | — | — |
| Non-permissible revenueInterest and excluded income | $90.7M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2026-06-30. Income statement as of 2025-12-31. Screened 2026-09-03.
A newer filing exists: our EDGAR watch has seen one since this screen and it is queued for re-screening. The figures below are from the filings named, not the newer one.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$4.3B
Assets· balance sheet as of 2026-06-30 -
Interest-bearing debt$487.4M
ConvertibleLongTermNotesPayable· balance sheet as of 2026-06-30 -
Cash and interest-bearing securities$3.9B
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent· balance sheet as of 2026-06-30 -
Receivables$0
no receivables tag reported in 3+ years (treated as $0)· balance sheet as of 2026-06-30 -
Revenue$0
RevenueFromContractWithCustomerExcludingAssessedTax· income statement as of 2025-12-31 -
Interest income (non-permissible)$90.7M
InvestmentIncomeInterest· income statement as of 2025-12-31 -
Market cap$2.3BMarket-data quote at screen time, 2026-09-03 · not a filing figure, so no link
What changed, and when
Verdict history for RVMDW. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for RVMDW has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| David Shaw | D. E. Shaw & Co. | $9M | 0.0% | 2026-09-30 |
| Israel Englander | Millennium Management | $1M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Not enough completed daily bars to compute pivots.
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Background via Yahoo Finance — informational, not part of the verdict.
No real edge — avoid
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 41 |
| 🕐 1H | BEARISH | 17 |
| ⏱ 15-Min | BEARISH | 71 |
| ⏲ 5-Min | BEARISH | 215 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
Key Statistics
From the nightly market snapshot, shown so the verdict sits beside the numbers it does not depend on.
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.